ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1129

Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy

Chary Lopez-Pedrera1, Tomás Cerdó2, María Ángeles Aguirre-Zamorano3, Laura Muñoz-Barrera1, Ismael Sánchez-Pareja2, Pilar Font1, María Carmen Ábalos-Aguilera4, Pedro Ortiz-Buitrago4, Nuria Barbarroja1, Eduardo Collantes1, Rafaela Ortega-Castro1 and Carlos Pérez-Sánchez1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 4Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Lupus nephritis, proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. At present, our knowledge of serum protein patterns related to cardiovascular (CV) risk and renal involvement is still limited.To characterize clinical phenotypes in SLE patients through serological analysis of proteomic profiles.

Methods: Proximity extension immunoassay (PEA, Olink) was used to assess the serum levels of one hundred and eighty-four inflammation and organ damage-related proteins in patients with SLE (n = 141) and age-matched healthy donors (HD) (n = 28). In parallel, an extensive clinical and analytical profile of recruited subjects was performed. To evaluate the contribution of molecular profiles to disease features, unsupervised machine learning clustering analyses were developed. Gene ontology enrichment analysis were also carried out to interrogate the biological meaning associated with the molecular signatures identified.

Results: Several circulating proteins related to inflammation and organ damage were coordinately altered in the serum of SLE patients in relation to HD. Unsupervised clustering analyses differentiated 2 patients clusters presenting different proteomic profiles. Clinically, although no differences were found in terms of age, gender, disease duration, or treatments, patients belonging to cluster 1 were characterized by higher status of disease activity (SLEDAI over 5,3) and prevalence or positivity for anti-ENA and anti-dsDNA antibodies than patients belonging to cluster 2. These patients showed a preponderance of lupus nephritis (LN) and proteinuria. Besides, this cluster comprised SLE patients with higher CV risk, revealed by an elevated incidence of dyslipidemia, obesity and hypertension. Sixty-seven proteins were found deregulated between clusters, including inflammatory mediators (cytokines, chemokines and regulatory proteins of leukocyte activity) and numerous proteins related to both, renal disease and increased CV risk. Of note, fifty proteins were found significantly altered between patients with LN vs patients without LN. Logistic regression analyses identified several proteins which levels distinguished lupus nephritis patients with high accuracy, including several proteins involved in renal damage, not previously reported in the serum of SLE patients.

Conclusion: 1) This highly sensitive proteomic analysis in the serum of SLE identified molecular patterns distinguishing patients with high disease activity and active LN, and including several novel candidate proteins, whose exact role and suitability as biomarkers in SLE deserve further investigation. 2) Combination of novel and traditional disease-specific biomarkers may improve diagnosis and management of SLE.

Supported by ISCIII (PI21/005991 and RICOR-RD21/0002/0033) co-financed by FEDER


Disclosures: C. Lopez-Pedrera, None; T. Cerdó, None; M. Aguirre-Zamorano, None; L. Muñoz-Barrera, None; I. Sánchez-Pareja, None; P. Font, None; M. Ábalos-Aguilera, None; P. Ortiz-Buitrago, None; N. Barbarroja, None; E. Collantes, None; R. Ortega-Castro, None; C. Pérez-Sánchez, None.

To cite this abstract in AMA style:

Lopez-Pedrera C, Cerdó T, Aguirre-Zamorano M, Muñoz-Barrera L, Sánchez-Pareja I, Font P, Ábalos-Aguilera M, Ortiz-Buitrago P, Barbarroja N, Collantes E, Ortega-Castro R, Pérez-Sánchez C. Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/integrated-high-throughput-proteomics-and-machine-learning-analysis-in-systemic-lupus-erythematosus-patients-identify-distinctive-clinical-profiles-and-novel-biomarkers-related-to-cardiovascular-risk/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/integrated-high-throughput-proteomics-and-machine-learning-analysis-in-systemic-lupus-erythematosus-patients-identify-distinctive-clinical-profiles-and-novel-biomarkers-related-to-cardiovascular-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology